Tau-stabilizing small molecules for primary tauopathies

What if we could intervene in tauopathies before harmful tau pathology takes hold?

Dr. Markus Zweckstetter and his team at brainQr Therapeutics are developing small molecule compounds called Tau-Stabilizers. As inaugural awardees of Sprint to Lead, a program of the Rainwater Charitable Foundation, they aim to keep tau in its healthy, native state and potentially limit its spread in the brain.

The approach
The molecules might bind tau in its native state while preserving its normal interactions, including those with microtubules, and could reduce tau’s tendency to form or spread disease-associated assemblies. The approach seeks to intervene even earlier in the disease process. The team’s starting point is a brain-penetrant, tau-stabilizing compound.

The project
Over the one-year grant, the team will examine how the chemistry must change for FTLD-tau, develop and compare related compounds, and assess their effects in disease-relevant systems. Finally, they will test whether an optimized molecule strongly limits tau spreading in a mouse model. The long-term objective is an oral medication.

The program
The inaugural Sprint to Lead program of the Rainwater Charitable Foundation supports the hit-to-lead and lead-optimization stages of drug discovery. Three teams each receive $350,000 for a one-year project.

The work brings together insights from physics, structural biology, and drug discovery. This kind of bold, interdisciplinary thinking is needed to identify new therapeutic approaches for tau-driven FTD and other primary tauopathies.

Learn more about Dr. Zweckstetter’s work (opens in a new window)
Portfolio company brainQr Therapeutics